3/20
06:00 pm
nktr
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Low
Report
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/14
08:02 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
3/13
12:08 pm
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
3/13
08:13 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
3/12
10:37 pm
nktr
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Medium
Report
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
3/12
08:36 pm
nktr
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates [Yahoo! Finance]
Medium
Report
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates [Yahoo! Finance]
3/12
04:44 pm
nktr
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/12
04:15 pm
nktr
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
3/5
06:42 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
Low
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
3/5
06:00 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
Low
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
2/26
07:19 am
nktr
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata [Yahoo! Finance]
Medium
Report
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata [Yahoo! Finance]
2/26
07:00 am
nktr
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
High
Report
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
2/25
12:14 pm
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
2/25
08:00 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
2/24
07:32 am
nktr
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th [Yahoo! Finance]
High
Report
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th [Yahoo! Finance]
2/24
07:32 am
nktr
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus [Yahoo! Finance]
High
Report
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus [Yahoo! Finance]
2/24
07:00 am
nktr
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
High
Report
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
2/24
07:00 am
nktr
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
High
Report
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
2/10
07:18 am
nktr
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis [Yahoo! Finance]
High
Report
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis [Yahoo! Finance]
2/10
07:00 am
nktr
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Medium
Report
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
1/31
11:04 pm
nktr
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
1/13
08:04 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
1/10
07:00 am
nktr
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
Medium
Report
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
1/9
06:58 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at B. Riley to a "strong-buy" rating.
1/8
08:00 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at B. Riley. They set a "buy" rating and a $4.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at B. Riley. They set a "buy" rating and a $4.00 price target on the stock.